## Pneumocystis jirovecii Pneumonia (PCP): First-Line Treatment ### Clinical Context The patient has confirmed PCP with consolidation pattern on CXR. Although she is not explicitly stated to be immunocompromised, severe chemotherapy-induced immunosuppression (day 10 post-treatment) is sufficient risk. The consolidation with air bronchograms is typical of PCP. ### Why TMP-SMX? **Key Point:** Trimethoprim-sulfamethoxazole (TMP-SMX) is the gold-standard first-line agent for both treatment and prophylaxis of *Pneumocystis jirovecii* pneumonia worldwide, including India. **High-Yield:** TMP-SMX mechanism in PCP: - Trimethoprim inhibits dihydrofolate reductase - Sulfamethoxazole inhibits dihydropteroate synthase - Dual blockade of folate synthesis is lethal to *P. jirovecii* **Mnemonic:** **TMPSMX** = **T**rimethoprim + **S**ulfamethoxazole = **M**ultiple **X**enobiotic targets (folate pathway) ### Treatment Hierarchy for PCP | Agent | Role | Indication | |-------|------|------------| | **TMP-SMX** | **First-line, both treatment & prophylaxis** | All PCP cases (mild to severe) | | Pentamidine | Second-line | TMP-SMX intolerance/allergy | | Atovaquone | Third-line (weak) | Mild PCP + TMP-SMX intolerance | | Clindamycin + primaquine | Alternative | Mild-moderate PCP + TMP-SMX intolerance | **Clinical Pearl:** High-dose TMP-SMX (15–20 mg/kg/day trimethoprim component) is used for treatment; lower doses (1–2 DS tablets daily) for prophylaxis. Adjunctive corticosteroids (prednisone) are added if PaO~2~ < 70 mmHg or A-a gradient > 35 mmHg. **Warning:** Do not confuse prophylaxis regimens (CD4 < 200 in HIV) with treatment regimens — treatment requires higher doses and longer duration (21 days).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.